Drug intelligence / Profile preview

GB-NDA

Development stage: Preclinical
Lead developer: GlycosBio
Administration: Oral

Overview

GB-NDA is a lipid-engineered nutraceutical candidate developed by GlycosBio for the management of acne. It is formulated using the company's proprietary Activated Oil System, a technology designed to enhance the bioavailability and delivery of active nutritional components. Categorized as a functional food or nutraceutical rather than a traditional pharmaceutical, GB-NDA does not have a defined molecular target but aims to address acne symptoms through optimized oral delivery of specific lipids or nutritional actives. The candidate is currently in clinical development as part of GlycosBio's nutrition-focused pipeline.

Beyond the preview

Go deeper on GB-NDA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-NDA.

Explore the full profile